S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Laser breakthrough could send stock soaring 2,467% (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Laser breakthrough could send stock soaring 2,467% (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Laser breakthrough could send stock soaring 2,467% (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Laser breakthrough could send stock soaring 2,467% (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Laser breakthrough could send stock soaring 2,467% (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Laser breakthrough could send stock soaring 2,467% (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Laser breakthrough could send stock soaring 2,467% (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Laser breakthrough could send stock soaring 2,467% (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Laser breakthrough could send stock soaring 2,467% (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
NASDAQ:CERE

Cerevel Therapeutics (CERE) Earnings Date, Estimates & Call Transcripts

$21.83
-0.34 (-1.53%)
(As of 09/29/2023 ET)
Compare
Today's Range
$21.71
▼
$22.43
50-Day Range
$20.26
▼
$30.73
52-Week Range
$19.85
▼
$35.98
Volume
833,700 shs
Average Volume
712,640 shs
Market Capitalization
$3.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.90
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
Nov. 14Estimated
Actual EPS
(Aug. 2)
-$0.63 Beat By $0.02
Consensus EPS
(Aug. 2)
-$0.65
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

CERE Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CERE Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Cerevel Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($0.67)($0.63)($0.65)
Q2 20232($0.64)($0.60)($0.62)
Q3 20232($0.67)($0.61)($0.64)
Q4 20232($0.69)($0.62)($0.66)
FY 20238($2.67)($2.46)($2.57)
Q1 20241($0.67)($0.67)($0.67)
Q2 20241($0.63)($0.63)($0.63)
Q3 20241($0.67)($0.67)($0.67)
Q4 20241($0.69)($0.69)($0.69)
FY 20244($2.66)($2.66)($2.66)

CERE Earnings Date and Information

Cerevel Therapeutics last posted its earnings results on August 2nd, 2023. The biotechnology company reported ($0.63) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.02. Cerevel Therapeutics has generated ($2.55) earnings per share over the last year (($2.55) diluted earnings per share). Earnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.58) to ($2.69) per share. Cerevel Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 14th, 2023 based off prior year's report dates.

Cerevel Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/14/2023
Estimated)		------- 
8/2/2023Q2 2023($0.65)($0.63)+$0.02($0.63)--    
5/3/2023Q1 2023($0.67)($0.67)-($0.67)--    
2/22/2023Q4 2022($0.64)($0.59)+$0.05($0.59)--
11/8/2022Q3 2022($0.62)($0.66)($0.04)($0.66)--
8/1/2022Q2 2022($0.48)($0.62)($0.14)($0.61)--    
5/10/2022Q1 2022($0.44)($0.46)($0.02)($0.46)--    
3/1/2022Q4 2021($0.41)($0.40)+$0.01($0.40)--    
11/10/2021Q3 2021($0.40)($0.43)($0.03)($0.43)--    
8/11/2021Q2 2021($0.41)($0.42)($0.01)($0.42)--    
5/16/2021Q1 2021($0.41)($0.40)+$0.01($0.40)--  
3/24/2021Q4 2020($0.37)($0.27)+$0.10($0.27)--  
11/16/2020Q3 2020-($4.83)($4.83)($4.17)--












Cerevel Therapeutics Earnings - Frequently Asked Questions

When is Cerevel Therapeutics's earnings date?

Cerevel Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 14th, 2023 based off last year's report dates. Learn more on CERE's earnings history.

Did Cerevel Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Cerevel Therapeutics (NASDAQ:CERE) reported ($0.63) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.65) by $0.02. Learn more on analysts' earnings estimate vs. CERE's actual earnings.

How can I listen to Cerevel Therapeutics's earnings conference call?

The conference call for Cerevel Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Cerevel Therapeutics's conference call transcript?

The conference call transcript for Cerevel Therapeutics's latest earnings report can be read online. Read Transcript

How much profit does Cerevel Therapeutics generate each year?

Cerevel Therapeutics (NASDAQ:CERE) has a recorded net income of -$351.51 million. CERE has generated -$2.55 earnings per share over the last four quarters.

What is Cerevel Therapeutics's EPS forecast for next year?

Cerevel Therapeutics's earnings are expected to decrease from ($2.58) per share to ($2.69) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:CERE) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -